These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17664326)

  • 21. Expanding the role of the microscopic observation drug susceptibility assay in tuberculosis and HIV management.
    Minion J; Pai M
    Clin Infect Dis; 2010 Apr; 50(7):997-9. PubMed ID: 20192726
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis.
    Gupta A; Meena J; Sharma D; Gupta P; Gupta UD; Kumar S; Sharma S; Panda AK; Misra A
    Mol Pharm; 2016 Sep; 13(9):3247-55. PubMed ID: 27463245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence, not resistance, is the cause of loss of isoniazid effect.
    Wallis RS; Palaci M; Eisenach K
    J Infect Dis; 2007 Jun; 195(12):1870-1; author reply 1872-3. PubMed ID: 17492604
    [No Abstract]   [Full Text] [Related]  

  • 24. [Bactericidal therapy in patients with tuberculosis].
    Krasnov VA; Ursov IG
    Probl Tuberk Bolezn Legk; 2004; (3):21-6. PubMed ID: 15338895
    [No Abstract]   [Full Text] [Related]  

  • 25. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
    Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL
    J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Incidence of resistant mutants of Mycobacterium tuberculosis (MT) strains from different areas of Rumania. Bacteriological study--epidemiological aspects].
    Anastasatu C; Băicoianu S; Teodorescu A
    Arch Roum Pathol Exp Microbiol; 1970; 29(1):212-22. PubMed ID: 4998673
    [No Abstract]   [Full Text] [Related]  

  • 27. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
    Weiner M; Benator D; Burman W; Peloquin CA; Khan A; Vernon A; Jones B; Silva-Trigo C; Zhao Z; Hodge T;
    Clin Infect Dis; 2005 May; 40(10):1481-91. PubMed ID: 15844071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and evaluation of rifabutin analogs against Mycobacterium avium and H(37)Rv, MDR and NRP Mycobacterium tuberculosis.
    Figueiredo R; Moiteiro C; Medeiros MA; da Silva PA; Ramos D; Spies F; Ribeiro MO; Lourenço MC; Júnior IN; Gaspar MM; Cruz ME; Curto MJ; Franzblau SG; Orozco H; Aguilar D; Hernandez-Pando R; Costa MC
    Bioorg Med Chem; 2009 Jan; 17(2):503-11. PubMed ID: 19119013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
    Jayaram R; Shandil RK; Gaonkar S; Kaur P; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Kantharaj E; Balasubramanian V
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2951-7. PubMed ID: 15273105
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Resistance to antitubercular drugs in Chile].
    Valenzuela MT; Scheel G; Ponce J; Lepe R; Velasco M; Valenzuela P
    Rev Med Chil; 1984 Jan; 112(1):76-80. PubMed ID: 6429808
    [No Abstract]   [Full Text] [Related]  

  • 31. [New antitubercular drugs].
    Krasucka-Kluźniak A
    Pneumonol Pol; 1990; 58(4-5):163-6. PubMed ID: 2168041
    [No Abstract]   [Full Text] [Related]  

  • 32. Drug resistance in tuberculosis.
    Ebrahim GJ
    J Trop Pediatr; 2007 Jun; 53(3):147-9. PubMed ID: 17526511
    [No Abstract]   [Full Text] [Related]  

  • 33. Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis.
    Yadav AB; Muttil P; Singh AK; Verma RK; Mohan M; Agrawal AK; Verma AS; Sinha SK; Misra A
    Tuberculosis (Edinb); 2010 May; 90(3):188-96. PubMed ID: 20382085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recall of isoniazid used for antimicrobial susceptibility testing for tuberculosis.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Sep; 49(34):780-2. PubMed ID: 10987246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
    Matteelli A; Olliaro P; Signorini L; Cadeo G; Scalzini A; Bonazzi L; Caligaris S; Tomasoni L; Tebaldi A; Carosi G
    Int J Tuberc Lung Dis; 1999 Nov; 3(11):1043-6. PubMed ID: 10587327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale for chemotherapy of tuberculosis and current recommendations.
    Kumar L
    Indian Pediatr; 1992 Nov; 29(11):1337-9. PubMed ID: 1294486
    [No Abstract]   [Full Text] [Related]  

  • 37. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
    Ahmad Z; Sharma S; Khuller GK
    FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dosing regimens in the treatment of tuberculosis.
    Blom-Bülow B
    Scand J Infect Dis Suppl; 1990; 74():258-61. PubMed ID: 2129066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic Adjuvant 4-Hexylresorcinol Enhances the Efficiency of Antituberculosis Drugs.
    Nikolaev YA; Mukhina TN; Potapov VD; Kuznetsov BB; El'-Registan GI; Firstova VV; Shemyakin IG; Manzenyuk OY
    Bull Exp Biol Med; 2024 Feb; 176(4):466-471. PubMed ID: 38488964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular medicine and treatment of tuberculosis].
    Perel'man MI; Khomiakov IuN; Kiselev VI; Severin ES; Pal'tsev MA
    Probl Tuberk; 2001; (5):5-7. PubMed ID: 11588966
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.